Closed-chest experimental porcine model of acute myocardial infarction–reperfusion

2009 ◽  
Vol 60 (3) ◽  
pp. 301-306 ◽  
Author(s):  
Armando Pérez de Prado ◽  
Carlos Cuellas-Ramón ◽  
Marta Regueiro-Purriños ◽  
J. Manuel Gonzalo-Orden ◽  
Claudia Pérez-Martínez ◽  
...  
2020 ◽  
Vol 26 (1) ◽  
pp. 88-99
Author(s):  
Vasileios Sousonis ◽  
Titika Sfakianaki ◽  
Argirios Ntalianis ◽  
Ioannis Nanas ◽  
Christos Kontogiannis ◽  
...  

Background: Allogeneic cardiosphere-derived cells (CDCs) exert cardioprotective effects when administered intracoronarily after reperfusion in animal models of acute myocardial infarction (AMI). The “no-reflow” phenomenon develops rapidly post-reperfusion and may undermine the efficacy of cell therapy, due to poor cell delivery in areas of microvascular obstruction (MVO). We hypothesized that CDC-induced cardioprotection would be enhanced by cell administration prior to reperfusion, when microvasculature is still relatively intact, to facilitate widespread cell delivery within the ischemic area. Methods and Results: We studied 81 farm pigs; 55 completed the specified protocols. A dose-optimization study in infarcted pigs demonstrated that the doses of 5 million and 10 million CDCs are the maximum safe doses that can be administered intracoronarily at 5 minutes prior to and at 5 minutes post-reperfusion, respectively, without aggravating MVO. Quantification of acute cell retention by polymerase chain reaction demonstrated that cell delivery prior to reperfusion resulted in higher cardiac cell retention compared to delivery post-reperfusion. We then performed a randomized, placebo-controlled study to assess the long-term efficacy of intracoronary infusion of 5 million allogeneic CDCs, delivered at 5 minutes prior to reperfusion, in a porcine model of AMI. The CDC therapy resulted in decreased scar size, improved regional systolic function, and attenuation of adverse cardiac remodeling (manifested as preserved global systolic function, preserved end-systolic volume, and decreased interstitial fibrosis) compared to placebo at 30 days post-MI. Conclusions: Dose-optimized intracoronary infusion of allogeneic CDCs prior to reperfusion in a porcine model of AMI is feasible, safe and confers long-term benefits.


2012 ◽  
Vol 40 (4) ◽  
pp. 285-289 ◽  
Author(s):  
Yang Peng ◽  
Li Jiahui ◽  
Li Aili ◽  
Wang Yong ◽  
Shi Zaixiang ◽  
...  

2008 ◽  
Vol 21 (5) ◽  
pp. 424-431 ◽  
Author(s):  
JON C. GEORGE ◽  
JONATHAN GOLDBERG ◽  
MATTHEW JOSEPH ◽  
NASREEN ABDULHAMEED ◽  
JOSHUA CRIST ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document